Evidence-based clinical guidelines addressing primary cutaneous concerns. Each profile is synthesized from peer-reviewed dermatological literature, detailing underlying pathophysiology, therapeutic active compounds, contraindicated ingredients, and verified lab-tested formulations.
Key Clinical Takeaways (Diagnostic Summary)
Clinical Management Principles Across Dermatological Phenotypes
•
Barrier Integrity First: For active acne and erythematous rosacea, repairing the stratum corneum barrier reduces follicular hyperkeratinization and neurovascular flushing before initiating high-strength retinoids or keratolytics.
•
Excipient Screening: High-risk comedogenic esters (e.g., Isopropyl Myristate) and volatile drying alcohols (Alcohol Denat >5%) must be eliminated in reactive phenotypes to avoid rebound seborrhea.
•
Synergistic Photoprotection: Mineral Zinc Oxide combined with antioxidant Vitamin C and Niacinamide provides essential protection against matrix metalloproteinase-1 (MMP-1) collagen degradation and pigment stimulation.
1. Acne Vulgaris & Microcomedones
Clinical Code: ICD-11 FA40
A multifactorial inflammatory disease of the pilosebaceous unit characterized by abnormal follicular keratinization, sebum hyperproduction, Cutibacterium acnes proliferation, and perifollicular immune activation.
Depletion of the intercellular stratum corneum lipid matrix (Ceramides, Cholesterol, and Free Fatty Acids). Results in transepidermal water evaporation (TEWL > 25 g/m²/h), dehydration, burning sensations, and pathogen translocation.
3. Cutaneous Photoaging, Solar Elastosis & Collagen Loss
Clinical Code: ICD-11 EJ20
Chronic ultraviolet (UVA/UVB) and High-Energy Visible (HEV) radiation exposure inducing reactive oxygen species (ROS), AP-1 transcription activation, and matrix metalloproteinase-mediated Type I and III collagen degradation.
First-Line Clinical Actives
Broad-Spectrum Mineral Filters: Micronized Zinc Oxide (≥9.0%) blocking 290–400nm radiation.
20% L-Ascorbic Acid: Neutralizes reactive hydroxyl radicals and acts as an essential cofactor for prolyl hydroxylase.
Neurovascular dysregulation, epidermal cathelicidin LL-37 cleavage overactivity, and demodex folliculorum hypersensitivity leading to persistent centrofacial erythema, telangiectasias, and stinging sensations.
First-Line Clinical Actives
Transparent Zinc Oxide: Calms cutaneous microvasculature without chemical heat generation.
Gallo RL, Granstein RD, Kang S, et al. Standard classification and pathophysiology of rosacea: The 2017 update. Journal of the American Academy of Dermatology (JAAD), 2018;78(1):148-155.
Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne Group. JAAD, 2009;60(5 Suppl):S1-S50.
Medical Specialty: Dermatology & Cutaneous Surgery
Board Certification: American Board of Dermatology (ABD) • Fellow, American Academy of Dermatology (FAAD)
Academic Appointment: Clinical Associate Professor of Cutaneous Medicine
Editorial Ethics: Neither Dr. Thorne nor Clinical Derma Lab accepts manufacturer compensation or sponsored reviews. All biometric tests are conducted independently.
